|
1
|
Raskov H, Pommergaard HC, Burcharth J and
Rosenberg J: Colorectal carcinogenesis-update and perspectives.
World J Gastroenterol. 20:18151–18164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yi M, Xu L, Jiao Y, Luo S, Li A and Wu K:
The role of cancer-derived microRNAs in cancer immune escape. J
Hematol Oncol. 13:1–14. 2020. View Article : Google Scholar
|
|
3
|
Kovats S, Main EK, Librach C, Stubblebine
M, Fisher SJ and DeMars R: A class I antigen, HLA-G, expressed in
human trophoblasts. Science. 248:220–223. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carosella ED, Moreau P, Le Maoult J, Le
Discorde M, Dausset J and Rouas-Freiss N: HLA-G molecules: From
maternal-fetal tolerance to tissue acceptance. Ad İmmunol.
81:199–252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tilburgs T, Evans JH, Crespo ÂC and
Strominger JL: The HLA-G cycle provides for both NK tolerance and
immunity at the maternal-fetal interface. Proc Natl Acad Sci USA.
112:13312–13317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loustau M, Anna F, Dréan R, Lecomte M,
Langlade-Demoyen P and Caumartin J: HLA-G neo-expression on tumors.
Front Immunol. 11:16852020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carosella ED, Moreau P, LeMaoult J and
Rouas-Freiss N: HLA-G: From biology to clinical benefits. Trends
İmmunol. 29:125–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Favier B, LeMaoult J, Lesport E and
Carosella ED: ILT2/HLA-G interaction impairs NK-cell functions
through the inhibition of the late but not the early events of the
NK-cell activating synapse. FASEB J. 24:689–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morandi F, Ferretti E, Bocca P, Prigione
I, Raffaghello L and Pistoia V: A novel mechanism of soluble HLA-G
mediated immune modulation: Downregulation of T cell chemokine
receptor expression and impairment of chemotaxis. PLoS One.
5:e117632010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yaghoubi N, Avval FZ, Khazaei M and
Aghaee-Bakhtiari SH: MicroRNAs as potential investigative and
predictive biomarkers in colorectal cancer. Cell Signal.
80:1099102021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Manaster I, Goldman-Wohl D, Greenfield C,
Nachmani D, Tsukerman P, Hamani Y, Yagel S and Mandelboim O:
MiRNA-mediated control of HLA-G expression and function. PLoS One.
7:e333952012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan Z, Randall G, Fan J, Camoretti-Mercado
B, Brockman-Schneider R, Pan L, Solway J, Gern JE, Lemanske RF,
Nicolae D and Ober C: Allele-specific targeting of microRNAs to
HLA-G and risk of asthma. Am J Hum Genet. 81:829–834. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu XM, Han T, Wang XH, Li YH, Yang HG,
Luo YN, Yin GW and Yao YQ: Overexpression of miR-152 leads to
reduced expression of human leukocyte antigen-G and increased
natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet
Gynecol. 202:592e1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peskoe SB, Barber JR, Zheng Q, Meeker AK,
De Marzo AM, Platz EA and Lupold SE: Differential long-term
stability of microRNAs and RNU6B snRNA in 12–20 year old archived
formalin-fixed paraffin-embedded specimens. BMC Cancer. 17:1–7.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of MiR-148a and MiR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou X, Zhao F, Wang ZN, Song YX, Chang H,
Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in
ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.PubMed/NCBI
|
|
19
|
Zheng G, Xiong Y, Xu W, Wang Y, Chen F,
Wang Z and Yan Z: A two-microRNA signature as a potential biomarker
for early gastric cancer. Oncol Lett. 7:679–684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi M, Cuatrecasas M, Balaguer F,
Hur K, Toiyama Y, Castells A, Boland CR and Goel A: The clinical
significance of MiR-148a as a predictive biomarker in patients with
advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH,
Lu CY, Juo SH and Wang JY: Clinical significance of microRNA-148a
in patients with early relapse of stage II stage and III colorectal
cancer after curative resection. Transl Res. 162:258–268. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanoun N, Delpu Y, Suriawinata AA, Bournet
B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L,
Cordelier P and Torrisani J: The silencing of microRNA 148a
production by DNA hypermethylation is an early event in pancreatic
carcinogenesis. Clin Chem. 56:1107–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hummel R, Hussey DJ, Michael MZ, Haier J,
Bruewer M, Senninger N and Watson DI: MiRNAs and their association
with locoregional staging and survival following surgery for
esophageal carcinoma. Ann Surg Oncol. 18:253–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jasinski-Bergner S, Stoehr C, Bukur J,
Massa C, Braun J, Hüttelmaier S, Spath V, Wartenberg R, Legal W,
Taubert H, et al: Clinical relevance of miR-mediated HLA-G
regulation and the associated immune cell infiltration in renal
cell carcinoma. Oncoimmunology. 4:e10088052015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Q, Luo G and Zhang X: MiR-148a
modulates HLA-G expression and influences tumor apoptosis in
esophageal squamous cell carcinoma. Exp Ther Med. 14:4448–4452.
2017.PubMed/NCBI
|
|
26
|
Hansel DE, Rahman A, Wilentz RE, Shih IM,
McMaster MT, Yeo CJ and Maitra A: HLA-G upregulation in
pre-malignant and malignant lesions of the gastrointestinal tract.
Internat J Gastrointest Cancer. 35:15–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swets M, König MH, Zaalberg A,
Dekker-Ensink NG, Gelderblom H, van de Velde CJ, van den Elsen PJ
and Kuppen PJK: HLA-G and classical HLA class I expression in
primary colorectal cancer and associated liver metastases. Hum
İmmunol. 77:773–779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murdaca G, Calamaro P, Lantieri F, Pigozzi
S, Mastracci L, Grillo F, Magnani O, Ceppa P, Puppo F and Fiocca R:
HLA-G expression in gastric carcinoma: Clinicopathological
correlations and prognostic impact. Virchows Arch. 473:425–433.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shahraki PK, Alavian-Mehr A and Farjadian
S: HLA-G: Facts and fictions. Asian Pac J Cancer Biol. 3:37–45.
2018. View Article : Google Scholar
|
|
30
|
Tuncel T, Karagoz B, Haholu A, Ozgun A,
Emirzeoglu L, Bilgi O and Kandemir EG: Immunoregulatory function of
HLA-G in gastric cancer. Asian Pac J Cancer Prev. 14:7681–7684.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Ye Z, Meng XQ and Zheng SS:
Expression of HLA-G in patients with hepatocellular carcinoma.
Hepatobiliary Pancreat Dis İnt. 10:158–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peng Y, Xiao J, Li W, Li S, Xie B, He J
and Liu C: Prognostic and clinicopathological value of human
leukocyte antigen G in gastrointestinal cancers: A meta-analysis.
Front Oncol. 11:6429022021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ishigami S, Natsugoe S, Miyazono F, Nakajo
A, Tokuda K, Matsumoto M, Okumura H, Douchi T, Hokita S and Aikou
T: HLA-G expression in gastric cancer. Anticancer Res.
26:2467–2472. 2006.PubMed/NCBI
|
|
34
|
Leelawat K, Engprasert S, Pongchai-rerk U,
Suthipintawong C and Leardkamolkarn V: No expression of human
leukocyte antigen G (HLA-G) in colorectal cancer cells. J Med Assoc
Thai. 87:816–818. 2004.PubMed/NCBI
|
|
35
|
Reimers MS, Engels CC, Putter H, Morreau
H, Liefers GJ, van de Velde CJ and Kuppen PJK: Prognostic value of
HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: A
retrospective cohort study. BMC Cancer. 14:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin A, Chen HX, Zhu CC, Zhang X, Xu HH,
Zhang JG, Wang Q, Zhou WJ and Yan WH: Aberrant human leucocyte
antigen-G expression and its clinical relevance in hepatocellular
carcinoma. J Cell Mol Med. 14:2162–2171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin A, Zhang X, Zhou WJ, Ruan YY, Xu DP,
Wang Q and Yan WH: Human leukocyte antigen-G expression is
associated with a poor prognosis in patients with esophageal
squamous cell carcinoma. Int J Cancer. 129:1382–1390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Farjadian S, Tabebordbar M, Mokhtari M,
Safaei A, Malekzadeh M and Ghaderi A: HLA-G expression in tumor
tissues and soluble HLA-G plasma levels in patients with
gastrointestinal cancer. Asian Pac J Cancer Prev. 19:2731–2735.
2018.PubMed/NCBI
|
|
39
|
Zhang RL, Zhang X, Dong SS, Hu B, Han QY,
Zhang JG, Zhou WJ, Lin A and Yan WH: Predictive value of different
proportion of lesion HLA-G expression in colorectal cancer.
Oncotarget. 8:107441–107451. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ye SR, Yang H, Li K, Dong DD, Lin XM and
Yie SM: Human leukocyte antigen G expression: As a significant
prognostic indicator for patients with colorectal cancer. Mod
Pathol. 20:375–383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo ZY, Lv YG, Wang L, Shi SJ, Yang F,
Zheng GX, Wen WH and Yang AG: Predictive value of HLA-G and HLA-E
in the prognosis of colorectal cancer patients. Cell İmmunol.
293:10–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
